Study on the Change of T-cell Subtype with Pegylated Interferon-α and Ribavirin Combined Therapy in Chronic Hepatitis C Patients
碩士 === 弘光科技大學 === 營養醫學研究所 === 104 === Patients with chronic hepatitis C virus (HCV) infection may progress toward cirrhosis, and liver cancer. A combination of pegylated interferon-α and ribavirin is the standard therapy for chronic HCV infection. However,there are currently no immunological predic...
Main Authors: | Shih chiaju, 施佳如 |
---|---|
Other Authors: | 葉湘裕 |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/unc2zr |
Similar Items
-
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01) -
Predictors of anemia associated with pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
by: Ta-Wei Chen, et al.
Published: (2011) -
Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection
by: Mona H Ismail
Published: (2013-01-01) -
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01) -
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
by: Saleem Sana, et al.
Published: (2011-05-01)